Latikafusp represents a unique therapeutic method for addressing specific malignancies, particularly instances involving fusion anaplastic lymphoma kinase proteins. This agent functions as an blocker of shortened anaplastic lymphoma kinase molecules, demonstrating promise in laboratory studies and early clinical trials. Its process of effect offers